<https://helda.helsinki.fi>

Use of fertility drugs in early onset female cancer survivors: a Finnish register-based study on 8,929 survivors

Melin, Johanna

2020-02-01

Melin, J., Madanat-Harjuoja, L., Hirvonen, E., Seppä, K., Malila, N., Pitkaniemi, J., Gissler, M. & Tiitinen, A. 2020, 'Use of fertility drugs in early onset female cancer survivors: a Finnish register-based study on 8,929 survivors', *International Journal of Cancer* 146, no. 3, pp. 829-838. <https://doi.org/10.1002/ijc.32346>

<http://hdl.handle.net/10138/314132>

<https://doi.org/10.1002/ijc.32346>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Use of fertility drugs in early onset female cancer survivors –A Finnish register-based study on 8,929 survivors

Short title: Fertility Treatments in Female Cancer Survivors

Corresponding author: Johanna Melin, Finnish Cancer Registry, Unioninkatu 22, 00130 Helsinki, Finland.

Electronic address: Johanna.Melin@cancer.fi. Tel. +358 50 5382526

Key words: Female cancer survivors, infertility, fertility treatments, ART

Abbreviations used: OI, Ovulation Induction; ART, Assisted Reproductive Technology; IVF, In vitro Fertilization; GnRH, Gonadotropin Releasing Hormone; PIC, Personal Identity Code; FCR, Finnish Cancer Register; CPR, Central Population Register; MBR, Medical Birth Register; RPM, Reimbursement Register for Prescribed Medicines; IRR, Incidence rate ratio; CI, Confidence Interval; ICCC3, International Classification of Childhood Cancer; Pyrs, Person years

Conflict of interest: No conflicts of interest exist.

Article Category: Cancer Epidemiology

Novelty and Impact: A previous study showed that early onset female cancer survivors were less likely to receive fertility treatments compared to siblings. However, according to our study, female cancer survivors are more likely to use fertility drugs compared to siblings in the last decade. The use of assisted reproductive technology was significantly increased, whereas the use of ovulation induction in cancer survivors was similar to that of siblings.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.32346

Use of fertility drugs in early onset female cancer survivors –A Finnish register-based study on 8,929 survivors

Johanna Melin MD ^{1,2}, Laura Madanat-Harjuoja MD, PhD ¹, Elli Hirvonen MSc ¹, Karri Seppä PhD ¹, Nea Malila MD, PhD ¹, Janne Pitkäniemi PhD ^{1,3}, Mika Gissler PhD ^{4,5}, Aila Tiitinen MD, PhD ⁶

¹ Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland

² Department of Obstetrics and Gynecology, Kymenlaakso Central Hospital, Kotka, Finland

³ Department of Public Health, School of Medicine, University of Helsinki, Helsinki, Finland

⁴ National Institute for Health and Welfare, Information Services Department, Helsinki, Finland

⁵ Karolinska Institute, Department of Neurobiology, Care Science and Society, Stockholm, Sweden

⁶ Department of Obstetrics and Gynecology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland

Abstract

Advances in multimodality cancer treatments have increased the risk of long-term complications in early onset cancer survivors. For female cancer survivors these include diminished reproductive function, often resulting in a narrowed fertile window. The aim of this study was to evaluate the use of fertility treatments in cancer survivors (aged 0-39 years at diagnosis) compared to siblings. Data from Finnish registers on cancer, birth and prescribed medications were merged to identify 8,929 survivors and 9,495 siblings without previous deliveries. Fertility drug purchases from 1993 to 2012 at the age of 16-41 years were included. A Poisson regression model was used to estimate incidence rate ratios (IRR) for the use of fertility drugs, adjusting for age and calendar time at fertility drug purchase. Fertility treatments were more common in survivors compared to siblings, as 6.1% of survivors compared to 3.8% of siblings had bought fertility drugs (IRR 1.43, 95% confidence interval [CI] 1.25-1.65). A sub-classification of fertility treatments into ovulation inductions and assisted reproductive technology (ART), showed increased use of ART (IRR 2.41, 95 % CI 1.97-2.96), whereas the use of ovulation induction was similar in survivors and siblings. Analyses by calendar time periods showed the use of ART to be significantly higher in the most recent decade, from 2003 onwards. We conclude that cancer survivors have an increased risk for subfertility, which is why fertility counselling is important. However, our results mirror a more active approach among clinicians towards fertility treatments in cancer survivors during the most recent years.

Introduction

The population of early onset cancer survivors has been increasing over the past four decades, with 5-year survival rates reaching 80% in Finland as well as in Western Europe.^{1, 2, 3} As survival rates increase, so does the risk for chronic health conditions due to previous exposure to toxic anti-cancer treatments. Of these late effects, gonadal dysfunction and reduced fertility have been reported as major concerns among cancer survivors.⁴ A previous study⁵ found that cancer treatments, especially abdominal radiation and chemotherapy with alkylating agents, may damage the ovaries, leading to diminished ovarian reserve, a narrowed fertile window and even premature ovarian insufficiency.

Many studies have shown reduced parenthood and pregnancy rates in cancer survivors compared to siblings or the general population.⁶⁻⁹ There are, however, only a few studies focusing on infertility and even less on the use of fertility treatments among cancer survivors.^{10,11} One of them reported an increased risk for clinical infertility (defined as the inability to conceive after at least one year of unprotected intercourse during the fertile phase of the menstrual cycle) among survivors compared to siblings.¹⁰ In this study, survivors were as likely as their siblings to seek medical help for their infertility, but less likely to receive fertility treatments.¹⁰ However, a previous study with the Finnish cohort¹¹ found that cancer survivors giving birth were more likely to undergo fertility treatments than their siblings were. Time elapsed from cancer treatment played a central role, with increasing use of fertility treatments over time.

The aim of our study was to investigate whether female cancer survivors (diagnosed with cancer at the age of 0-39 years) receive more fertility treatments or fertility preservation than their siblings do, and if type of used fertility drug differed from that of siblings by the use of various Finnish register databases (FCR, CPR, MBR and RPM).

Materials and Methods

In this retrospective, register-based study, we used data from four different national population-based registers: The Finnish Cancer Registry (FCR), the Central Population Register (CPR), the Medical Birth Register (MBR) and the Reimbursement Register for Prescribed Medicines (RPM). The registers were linked using the personal identity code (PIC) given to all Finnish citizens and residents.

Registers

The FCR is a population based national register on incident cancer cases since 1953. The coverage of the FCR is high, 96% for solid tumors and 86% for hematological malignancies. Of all cancers, 93% were morphologically verified.¹² Data on cancer patients include: the PIC, details on cancer (site, histology and malignancy), treatment data (radiotherapy, chemotherapy, surgery and hormonal) and month as well as year of diagnosis. Clinical information is mainly provided by the treating physician and the histological data is notified by the pathology department. Childhood cancer diagnoses are categorized using the International Classification of Childhood Cancer (ICCC3).¹³

The CPR was founded in 1969 and computerized registration began in 1971. The register is national, covering all citizens and residents in Finland and includes data on residential history and death. Individuals born in 1955 or thereafter can be linked reliably to their parents, siblings and offspring.

The MBR was established in 1987 and contains detailed information on all mothers giving birth as well as their children. Data is collected at the delivery hospital, using the maternity records of the mothers and includes information on all live births and stillbirths with a birth weight of more than 500 g or a pregnancy lasting for at least 22 weeks are registered. Data on less than 0.1% of newborns are missing in the Medical Birth Register.¹⁴

The RPM has registered all purchased drugs since 1993. All refundable medications prescribed by public as well as by private health care providers are registered. Data include the purchase date of the prescription drug, the price of the medication and package size. All the drugs have been listed according to Anatomical Therapeutic Chemical codes (ATC codes) categories released by the World Health Organization. A study¹⁵ comparing data from RPM and aggregated statistics of in vitro fertilization (IVF) in Finland, found the coverage of this register to be good.¹⁵

Study design

From the FCR, we identified 23,125 female cancer patients (hereafter referred to as survivors) diagnosed with a malignant neoplasm or benign brain tumor under the age of 40 years between January 1953 and December 2012 (Figure 1). Female siblings of survivors were identified from the CPR by maternal link using the PICs. We identified 20,542 female siblings of survivors. To eliminate possible influences of pregnancy history on the endpoint studied, we only included women without biological children before the time-point of fertility drug purchase. By linkage to the MBR, we could exclude women who were multiparous and by linking to the RPM, we could exclude women who had delivered before fertility drug purchase. This way, we identified 16,640 survivors and 18,184 siblings without deliveries prior to drug purchase between 1993 and 2012.

We excluded all women who were not in the age range of 16-41 years between 1993 and 2012 (when information on fertility drug purchase was available), and were left with 8,929 survivors and their 9,495 siblings. Censoring events before drug purchase (Figure 1) included a pregnancy of more than 22 weeks or birth (a notification in the MBR), death, emigration, notification of aromatase inhibitor medication as a long-term anti-cancer treatment (registered in the RPM) or cancer diagnosis in a sibling. After these exclusions, the follow-up time was 48,638 person years for survivors and 56,102 person years for siblings.

The primary outcome analyzed was any fertility treatment, which was further sub-divided into ovulation induction (OI) and assisted reproductive technology (ART). ART refers to in vitro fertilization, intracytoplasmic sperm injection and frozen embryo transfer. The most commonly used oral OI drugs are clomiphene citrate and aromatase inhibitors whereas gonadotropins are injectable drugs used for OI. These drugs are typically used for 3-6 cycles, commonly in combination with intrauterine insemination. During ART, a combination of gonadotropin releasing hormone (GnRH) analogues and gonadotropins is used. To sub-categorize fertility treatments in women as either OI or ART, we used information on fertility drug purchase during the following 21 days after an initial fertility drug purchase.

A fertility treatment was classified as OI in the following cases:

- Clomiphene citrate or aromatase inhibitor use, without use of any other fertility drug during the following 21 days
- Gonadotropin use, without use of GnRH analogues

Fertility treatments were classified as ART in the following cases:

- A GnRH agonist or GnRH antagonist was the first drug used
- Gonadotropin use in combination with GnRH analogues

In our data, time to event of four survivors was censored after being categorized into the any treatment group, but before categorization into the OI or the ART treatment group. Two siblings entered follow up after categorization into the any treatment group, but before categorization into the OI or ART treatment group (as their matched survivor received her cancer diagnosis after the sibling's initial fertility drug purchase). Therefore, the numbers in the different treatment categories do not always add up to the numbers in the any treatment group (Table 1).

Statistical analysis

In this study, use of fertility treatments in cancer survivors and their siblings, was based on information on fertility drug purchase. We estimated incidence rates of fertility treatments (the number of events per 10,000 person-years) by time period (1993-1997, 1998-2002, 2003-2007 and 2008-2012) and attained age (16-19, 20-24, 25-29, 30-34 and 35-41 years). Within each stratum of time period and attained age, we estimated the conditional probability of receiving a fertility treatment during a given age interval, given that the woman had not received fertility treatments before. We estimated incidence rate ratios (IRR) of fertility treatments in survivors compared to siblings, with 95% confidence intervals (CI) using Poisson regression models, adjusting for time period and attained age. A single, overall IRR, assuming no heterogeneity, was estimated. In addition, we fitted models that allowed heterogeneity in IRR by time period and age at fertility drug purchase and reported relative excess risk compared to a baseline IRR (age 20-24 years, period 1993-1997). The statistical significance of the heterogeneity was tested using the likelihood ratio test and the level of statistical significance was set at $p < 0.05$. We plotted smoothed incidence rates of the different fertility treatments by age and time period, using generalized additive models.¹⁶

All analyses were conducted using R version 3.5.1.

Ethics

The National Institute for Health and Welfare (Dnr THL/1/5.05.00/2014) and the Social Insurance Institution (Dnr KELA/69/522/2014) approved this study protocol and granted a permit for the study. The permit process included an ethical evaluation.

Results

The descriptive and treatment characteristics of female cancer survivors are presented in Table 1. Most survivors in our data (62.7%) were diagnosed with cancer between 1993 and 2012 and the majority in

adulthood at the age of 25-39 years (59.1%). Childhood cancer survivors (0-14 years when diagnosed) accounted for 15.7% of all survivors, and adolescents and young adults (15-24 years when diagnosed) for 25.2%. The largest diagnostic group based on the ICC3 classification consisted of carcinomas and other malignant epithelial neoplasms (50.6%). This group included breast cancers (15.7%), cancer of the thyroid gland (11.0%) and melanomas of the skin (7.9%) among others. The second largest diagnostic group consisted of lymphomas (13.0%), followed by tumors of the central nervous system (10.9%) and leukemia (7.7%).

In our data (Table 1), most fertility treatments (65.3%) were given to adult cancer survivors and most often (44.7%) within three years of cancer diagnosis. Also most ART cycles were given to survivors who had been diagnosed with cancer within three years (60.1%). Of all cancer survivors, 49 (9.1%) were prescribed fertility drugs within 2 months after cancer diagnosis. Exploring the different cancer types, breast cancer survivors received the largest proportion of the fertility treatments (40.9%), the majority of ART cycles (55.2%) and a much smaller proportion of OI (12.7%).

Of all cancer survivors, 541 (6.1%) were prescribed fertility drugs (Table 2). A majority, 64.3% of these fertility treatments, were ART. Of all siblings, 358 (3.8%) received fertility treatments, of which 39.4% were ART. As shown in Table 2, there was an overall increased use of fertility treatments in cancer survivors compared to siblings (IRR 1.43, 95% CI 1.25-1.65). A sub-classification of fertility treatments showed that the use of ART was significantly higher in cancer survivors (IRR 2.41, 95% CI 1.97-2.96) compared to siblings, whereas there was no increase in the use of OI (IRR 0.83, 95% CI 0.68-1.02).

We observed statistically significant heterogeneity in IRR between age-groups and time periods in any fertility treatment and ART (Table 2). Compared to the first period, IRR between survivors and siblings was significantly larger in the most recent time periods. For example, IRR for use of ART was 3.39-fold (95% CI 1.79-6.41) in 2003-2007 compared to that in 1993-1997. Regarding the effect of age, IRR for the use of ART

was significantly smaller among 30-34 year old women (0.41-fold, 95% CI 0.17-0.97) as well as 35-41 year old women (0.35-fold, 95% CI 0.15-0.82) compared to those aged 20-24 years (Table 2). The IRR for OI was not significantly affected by time period or age.

In Figure 2, the incidence rates of OI and ART are plotted against age at fertility drug purchase in different time periods. The incidence rates are given in table 3 (OI) and 4 (ART). In 1993-1997, the incidence rates for both OI and ART in survivors and siblings were quite similar. In OI, the same pattern could also be observed in 1998-2002. With regard to ART in 1998 to 2002, an increasing though non-significant gap in the incidence rates of survivors and siblings was visible. ART was more common among survivors than siblings in all age-groups. The biggest difference in incidence rate during this time period was among women 25-29 years of age, as the incidence rate for survivors was 47/10,000 person years (Pyr) compared to 26/10,000 Pyr in siblings. During 2003 to 2007, the difference in incidence rates for ART became significant and was at its highest. For a survivor aged 25-29 years the incidence rate of receiving ART was 85/10,000 Pyr whereas it was 11/10,000 Pyr among siblings. At the age of 30-34 years the incidence rate was 150/10,000 Pyr among survivors and 60/10,000 Pyr among siblings. The incidence rates for OI were quite similar in 2003-2007 and 2008-2012, siblings received more OI, especially in the higher age groups. During the most recent time period of 2008-2012, the difference in incidence rates decreased for ART, still remaining significantly higher in survivors compared to siblings in all age-groups.

Discussion

In our study, cancer survivors had a more than 1.4-fold use of overall fertility treatments compared to siblings. A sub-classification of overall fertility treatments into OI and ART revealed that this could be explained by ART, for which the use was more than 2.4-fold in survivors compared to siblings. Concerning OI, there was no difference between survivors and siblings and the risk was unaffected by age or time period of fertility drug purchase.

A report from the Childhood Cancer Survivor Study¹⁰ found a 48% increased risk for clinical infertility in cancer survivors, but on the contrary to our result cancer survivors were less likely than their siblings to be prescribed drugs for fertility treatment (RR 0.57, 95% CI 0.46-0.70). This study, however, evaluated fertility treatments between 1992 and 2004 and does not necessary reflect the situation in recent years.

Furthermore, this study only included women younger than 21 years of age at cancer diagnosis whereas our study cohort includes women aged up to 40 years at cancer diagnosis.

Our previous study found that Finnish female cancer survivors giving birth (aged 0-34 years at cancer diagnosis) had an almost two-fold risk for fertility treatments, during 2004-2013, compared to siblings.¹¹

Survivors diagnosed as adults (at ages 25-34 years) had the highest odds for use of fertility treatments (OR 2.31, 95% CI 1.01-5.32) whereas childhood cancer survivors (aged 0-14 years) had the lowest risk compared to siblings. Time elapsed from cancer treatment played a central role, increasing the need for fertility treatments compared to siblings, suggesting that cancer therapies might lead to diminished ovarian reserve. This finding is supported by another recent study¹⁷, in which the likelihood of a live birth was reduced after ART with autologous oocytes in cancer survivors. However, after ART with donor oocytes, the live birth rate was similar to that of siblings.

To our knowledge, there are no published reports in the literature that uses a nationwide drug prescription register to explore use of fertility treatments in cancer survivors and their siblings. Studying fertility treatments in cancer survivors is of clinical importance, since they reflect possible gonadal damage caused by cancer treatments. They also mirror the attitudes of the treating physicians towards fertility treatments and fertility preservation in cancer survivors. In our study, 9.1% of all cancer survivors were prescribed fertility drugs within 2 months after cancer diagnosis, indicating that they were possibly fertility preservations. According to recent clinical guidelines, the possibility of infertility should be discussed with all cancer patients or their parents as early as possible after cancer diagnosis and when needed, fertility preservation should be considered.¹⁸ Pregnancy after cancer is generally considered safe and should not be

discouraged.¹⁹ When it comes to recommended time between end of cancer treatment and pregnancy, there is no standard time interval. Instead, individual timing, taking into account cancer type, extent of disease and risk of relapse is recommended.²⁰ Also the age of the woman and her ovarian reserve should be taken into account.²⁰ Regarding fertility treatments in female cancer survivors, one study on ART after breast cancer²¹ found no increased risk of relapse compared to survivors without fertility treatment. In this study, however, the majority of treatments consisted of oocyte donation and ovulation induction, which are procedures requiring no or low exposure to hormonal stimulation. In our study, 60% of all ART were given within three years of cancer diagnosis.

When assessing the ovarian reserve in sub-fertile women, measurement of FSH and AMH serum levels as well as antral follicle count by ultra-sound, is used.^{22, 23} Generally, OI is considered the first line treatment in ovulatory disorders and unexplained infertility, as it is less expensive, less invasive and easier to perform than ART. This was also the case for most siblings who received fertility treatments in our study. However, in survivors, the most common fertility treatment was ART, probably due to higher success rates than OI, especially when ovarian reserve is reduced. It is well known that cancer treatments, especially abdominal radiation and chemotherapy with alkylating agents, may damage the ovaries, leading to a narrowed fertile time window in cancer survivors.^{5, 11} This probably explains the increased use of more advanced fertility treatments (ART) at the cost of easier, less invasive fertility treatments (OI) in cancer survivors.

The main strength of our study is outcome ascertainment by use of a national drug prescription register to obtain outcome data, thus eliminating possible recall bias. Drugs classified as fertility drugs in our study are rarely used for other conditions. In our study, cancer survivors with a notification in the RPM of aromatase inhibitor use as an anti-cancer treatment (sometimes used in breast cancer) were censored from the study. Reliable population-based registers allowed identification of both cancer and sibling cohorts with no loss to follow-up, thus eliminating participation and selection bias. By comparing survivors with siblings, we were also able to adjust for familial factors that might interfere with the outcome studied.

The main limitation of our study is that information on the indication for fertility treatment (male and female factors) is missing both in survivors and in siblings. In our data, women with fertility treatments using autologous oocytes are included. We could not obtain information on use of donated oocytes for ART in our cohort. In addition, information on whether the fertility drugs were used for fertility preservation or as fertility treatments was not available. Furthermore, it is possible that some women, who were entitled to reimbursement for fertility drug purchase, chose not to apply for it. This group of women is likely to be small,¹⁵ as reimbursement is usually offered at the pharmacy and fertility drugs are often expensive. Limited duration of follow-up was available for women diagnosed with cancer in the most recent time period. In this study, results on pregnancy rates and live-birth rates after fertility treatments are not included. The results on successful fertility treatments resulting in a birth have been reported in a previous study of ours.¹¹ Lastly, we would have liked to adjust for socioeconomic status, smoking and body mass index but this information was unavailable in the RPM. As siblings were used as the comparison group, we suspect the effect of socioeconomic status to be marginal.

In conclusion, female cancer survivors receive more fertility treatments compared to their siblings, which may be explained by the increased use of ART. Time period of drug purchase played a central role and we observed a significantly increased use of ART in survivors compared to siblings from 2003 onwards. Our results mirror a more active approach among clinicians towards offering fertility treatments to cancer survivors in the most recent years.

Funding

This study was supported by a grant from the Cancer Foundation (Finland) and by a grant from the Gyllenberg Foundation.

Conflicts of interests

No conflicts of interests exist.

References

- (1) Madanat-Harjuoja LM, Pokhrel A, Kivivuori SM, Saarinen-Pihkala UM. Childhood cancer survival in Finland (1953-2010): a nation-wide population-based study. *Int J Cancer*. 2014 Nov 1; 135(9):2129-34.
- (2) Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos-Gragera R, Minicozzi P, Sanchez-Perez MJ, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-bonet R. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population based study. *Lancet Oncol*. 2014 Jan; 15(1):35-47.
- (3) Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, Maule MM, Merlett F, Gatta G. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. *Lancet Oncol* 2016 Jul; 17(7):896-906
- (4) Peate M, Meiser B, Hickey M, Friedlander M. The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. *Breast Cancer Res Treat* 2009; 116: 215-223.
- (5) Anderson R, Mitchell R, Kelsey T, Spears N, Telfer E, Wallace H. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. *Lancet Diabetes Endocrinol*. 2015 Jul;3(7):556-67
- (6) Madanat L, Malila N, Dyba T, Hakulinen T, Sankila R, Boice J, Lähteenmäki P. Probability of parenthood after early onset cancer: A population-based study. *Int J Cancer*. 2008 Dec 15; 123(12):2891-2898
- (7) Green D, Kawashima T, Stovall M, Leisenring W, Sklar C, Mertens A, Donaldson S, Byrne J, Robinson L. Fertility of female survivors of childhood cancer: A report from the Childhood cancer survivor study. *J Clin Oncol* 2009 Jun; 27(16):2677-2685
- (8) Stensheim H, Cvancarova M, Moller B, Fosså S. Pregnancy after adolescent and adult cancer: A population-based matched cohort study. *Int J. Cancer* 2011 Sep 1;129(5):1225-36

- (9) Anderson R, Brewster D, Wood R, Nowell S, Fischbacher C, Kelsey T, Wallace H. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. *Hum Reprod.* 2018 Jul; 33(7):1281-1290
- (10) Barton S, Najita J, Ginsburg E, Leisenring W, Stovall M, Weathers R, Sklar C, Robinson L, Diller L. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol* 2013; 14: 873-881.
- (11) Melin J, Madanat-Harjuoja L, Heinävaara S, Malila N, Gissler M, Tiitinen A. Fertility treatments among female cancer survivors giving birth – a Finnish register-based study. *Acta Oncol.* 2017 Aug; 56(8):1089-1093
- (12) Leinonen MK, Miettinen J, Heikkinen S, Pitkaniemi J, Malila N. Quality measures of the population-based Finnish cancer registry indicate sound data quality for solid malignant tumours. *Eur J Cancer* 2017; 77:31-9
- (13) Steliarova-Foucher E, Stiller C, Lacour B. International classification of childhood cancer, third Edition. *Cancer* 2005 Apr. 1; 103(7):1457-67
- (14) Gissler M, Shelley J. Quality of data on subsequent events in a routine medical birth register. *Medical Inform Internet Med.* 2002 Mar; 27(1):33-8
- (15) Gissler M, Klemetti R, Sevo`n T, Hemminki E. Monitoring of IVF birth outcomes in Finland: a data quality study. *BMC Med Inform Decis Mak.* 2004; 4:3
- (16) Wood S. Generalized Additive Models. 2006. New York: Chapman and Hall/CRC
- (17) Luke B, Brown M, Missmer S, Spector LG, Leach RE, Williams M, Koch L, Smith YR, Stern JE, Ball GD, Schymura MJ. Assisted reproductive technology use and outcomes among women with a history of cancer. *Hum Reprod* 2016; 31: 183-189.
- (18) Oktay K, Harvey BE, Partridge AH, Quinn GP, Reincke J, Taylor HS, Wallace WH, Wang ET, Loren AW. Fertility preservation in patients with cancer: ASCO Clinical practice guideline update. *J Clin Oncol* 2018 Jul; 36(19):1994-2001
- (19) Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G. Cancer, pregnancy and fertility: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013 Oct; 24(6):160-70

(20) Lambertini M, Del Mastro L, Pescio M, Andersen CY, Azim HA, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De stefano C, Wallace WH, Partridge AH, Anserini P. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016; 14:1

(21) Goldrat O, Kroman N, Peccatori F, Cordoba O, Pistilli B, Lidegaard O, Demeestere I, Azim HA. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015 Aug; 51(12):1490-6.

(22) Anderson RA, Wallace WHB. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fert.Steril. 2013 May; 99(6):1469-75

(23) Freour T, Barriere P, Masson D. Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer 2017 Mar; 74:1-8

Table 1

Descriptive characteristics and treatment characteristics of the female cancer survivor cohort

Characteristics	Survivors (N=8929) N (%)	Any fertility treatment (N=541) N (%)	OI (N=189) N (%)	ART (N=348) N (%)
Year of diagnosis				
1963-1972	53 (0.59)	6 (1.11)	2 (1.06)	4 (1.15)
1973-1992	3279 (36.72)	152 (28.10) ¹	96 (50.79)	54 (15.52)
1993-2012	5597 (62.68)	383 (70.79) ¹	91 (48.15)	290 (83.33)
Age at diagnosis				
0-14	1399 (15.67)	42 (7.76) ¹	28 (14.81)	13 (3.74)
15-24	2251 (25.21)	146 (26.99)	65 (34.39)	81 (23.28)
25-39	5279 (59.12)	353 (65.25) ¹	96 (50.79)	254 (72.99)
Time from diagnosis to treatment (years)				
0-2	N/A	242 (44.73) ¹	31 (16.40)	209 (60.06)
3-5	N/A	92 (17.01)	37 (19.58)	55 (15.80)
6-10	N/A	89 (16.45) ¹	50 (26.46)	38 (10.92)
11-41	N/A	118 (21.81) ¹	71 (37.57)	46 (13.22)
Cancer type				
Leukemia	688 (7.71)	22 (4.07) ¹	12 (6.35)	9 (2.59)
Lymphoma	1161 (13.00)	74 (13.68) ¹	24 (12.70)	49 (14.08)
Central Nervous System	970 (10.86)	30 (5.55)	17 (8.99)	13 (3.74)
Sympathetic Nervous System	77 (0.86)	1 (0.18)	1 (0.53)	0 (0.00)
Retinoblastoma	31 (0.35)	2 (0.37)	1 (0.53)	1 (0.29)
Renal Tumors	154 (1.72)	5 (0.92)	3 (1.59)	2 (0.57)
Malignant bone Tumors	140 (1.57)	7 (1.29)	5 (2.65)	2 (0.57)
Soft Tissue and other Sarcomas	338 (3.79)	13 (2.40)	7 (3.70)	6 (1.72)
Germ cell, Gonadal and Trophoblastic neoplasms	523 (5.86)	14 (2.59)	8 (4.23)	6 (1.72)
Carcinomas and other malignant epithelial neoplasms	4517 (50.59)	355 (65.62) ¹	101 (53.44)	253 (72.70)
Digestive system	532 (5.96)	23 (4.25)	16 (8.47)	7 (2.01)
Breast	1402 (15.70)	221 (40.85)	24 (12.70)	196 (56.32)
Melanoma of the skin	705 (7.90)	33 (6.47)	19 (10.05)	14 (4.02)
Thyroid gland	982 (11.00)	53 (9.80)	27 (14.29)	26 (7.47)
Others	896 (10.03)	25 (4.62)	15 (7.94)	10 (2.87)
Others	93 (1.04)	8 (1.48)	5 (2.65)	3 (0.86)
Missing	215 (2.41)	10 (1.85) ¹	5 (2.65)	4 (1.15)
Cancer treatment				
Chemotherapy	2903 (32.51)	212 (39.19) ¹	49 (25.93)	162 (46.55)
Radiotherapy	3204 (35.88)	235 (43.44) ¹	66 (34.92)	168 (48.27)
Surgery, only	3293 (36.88)	185 (34.20)	81 (42.86)	104 (29.89)
Other treatment	1121 (12.55)	58 (10.72) ¹	25 (13.23)	35 (10.06)

OI, Ovulation induction; ART, assisted reproduction technology

¹ time to event of 4 survivors were censored after being categorized into the any treatment

Table 2

Number of events and adjusted incidence rate ratios (IRRs) for different fertility treatments between 1993 and 2012 among female cancer survivors compared to their siblings

		Any treatment	OI	ART
Status				
Survivors N=8,929 N (%)		541 (6.06)	189 (2.12)	348 (3.90)
Siblings N=9,495 N (%)		358 (3.77)	219 (2.31)	141 (1.48)
Assuming no heterogeneity in IRR by age and time period (model M0)				
Overall IRR¹		1.43 (1.25-1.65)	0.83 (0.68-1.02)	2.41 (1.97-2.96)
Allowing heterogeneity in IRR by age and period (model M1)				
Baseline IRR¹ (age 20-24, period 1993-1997)		1.32 (0.75-2.30)	0.60 (0.25-1.42)	2.28 (0.92-5.68)
Relative excess risk compared to baseline IRR				
Age at drug purchase	16-19	-	-	-
	20-24	1	1	1
	25-29	0.66 (0.38-1.16)	1.69 (0.67-4.28)	0.62 (0.25-1.56)
	30-34	0.86 (0.48-1.54)	1.64 (0.67-4.04)	0.41 (0.17-0.97)
	35-41	0.59 (0.34-1.02)	1.14 (0.46-2.83)	0.35 (0.15-0.82)
Test for heterogeneity		p-value < 0.001 ²	p-value = 0.474 ²	p-value < 0.001 ²
Period of drug purchase	1993-1997	1	1	1
	1998-2002	1.24 (0.81-1.89)	0.91 (0.52-1.59)	1.73 (0.88-3.39)
	2003-2007	2.31 (1.53-3.49)	1.01 (0.55-1.87)	3.39 (1.79-6.41)
	2008-2012	1.73 (1.18-2.53)	0.89 (0.53-1.50)	2.65 (1.44-4.89)
Test for heterogeneity		p-value < 0.001 ³	p-value = 0.959 ³	p-value < 0.001 ³

IRR, incidence rate ratio; CI, confidence interval; OI, Ovulation induction; ART, Assisted reproductive technology

Bold indicates statistically significant incidence rate ratio

¹Adjusted for calendar period and age at possible fertility drug purchase

Incidence rate of treatment was modelled using Poisson regression with following models for covariate effects: M0: age + period + status + age*period, M1: age + period + status + age*period + age*status + period*status, M2: age + period + status + age*period + age*status, M3: age + period + status + age*period + period*status.

²p-value for comparing M1 vs M3 using likelihood ratio test

³p-value for comparing M1 vs M2 using likelihood ratio test

Table 3

Incidence and conditional probability of ovulation induction treatments in cancer survivors and siblings according to age and time period of drug purchase

		Ovulation induction (N)		Person years		Incidence rate/10 000 person years		Conditional probability %	
Age	Period	Survivors	Siblings	Survivors	Siblings	Survivors	Siblings	Survivors	Siblings
16-19	1993-1997	0	0	1233	1607	0	0	0	0
	1998-2002	0	0	1382	2160	0	0	0	0
	2003-2007	0	0	1411	2336	0	0	0	0
	2008-2012	0	0	1477	2792	0	0	0	0
	Total	0	0	5503	8895				
20-24	1993-1997	3	8	1570	1845	19	43	1	2.1
	1998-2002	2	4	2174	2650	9	15	0.5	0.8
	2003-2007	2	2	2274	3268	9	6	0.4	0.3
	2008-2012	1	4	2354	3624	4	11	0.2	0.6
	Total	8	18	8372	11387				
25-29	1993-1997	18	17	1618	2116	111	80	5.4	3.9
	1998-2002	9	13	1932	1907	47	68	2.3	3.4
	2003-2007	5	8	2463	2689	20	30	1	1.5
	2008-2012	10	14	2629	3307	38	42	1.9	2.1
	Total	42	52	8642	10019				
30-34	1993-1997	20	26	1873	2726	107	95	5.2	4.7
	1998-2002	11	18	1802	1978	61	91	3	4.4
	2003-2007	14	7	2064	1674	68	42	3.3	2.1
	2008-2012	19	25	2438	2304	78	109	3.8	5.3
	Total	64	76	8177	8682				
35-41	1993-1997	12	29	6914	7609	17	38	1.2	2.6
	1998-2002	12	12	4241	4620	28	26	2	1.8
	2003-2007	9	15	3542	2864	25	52	1.8	3.6
	2008-2012	18	14	3247	2026	55	69	3.8	4.7

	Total	51	70	17944	17119	
--	--------------	-----------	-----------	--------------	--------------	--

		ART (N)		Person years		Incidence rate/10 000 person years		Conditional probability %	
Age	Period	Survivors	Siblings	Survivors	Siblings	Survivors	Siblings	Survivors	Siblings
16-19	1993-1997	1	0	1233	1607	8	0	0.3	0
	1998-2002	1	0	1382	2160	7	0	0.3	0
	2003-2007	5	0	1411	2336	35	0	1.4	0
	2008-2012	6	0	1477	2792	41	0	1.6	0
	Total	13	0	5503	8895				
20-24	1993-1997	1	3	1570	1845	6	16	0.3	0.8
	1998-2002	7	0	2174	2650	32	0	1.6	0
	2003-2007	12	3	2274	3268	53	9	2.6	0.5
	2008-2012	11	2	2354	3624	47	6	2.3	0.3
	Total	31	8	8372	11387				
25-29	1993-1997	7	8	1618	2116	43	38	2.1	1.9
	1998-2002	9	5	1932	1907	47	26	2.3	1.3
	2003-2007	21	3	2463	2689	85	11	4.2	0.6
	2008-2012	25	8	2629	3307	95	24	4.6	1.2
	Total	62	24	8642	10019				
30-34	1993-1997	6	14	1873	2726	32	51	1.6	2.5
	1998-2002	12	11	1802	1978	67	56	3.3	2.7
	2003-2007	31	10	2064	1674	150	60	7.2	2.9
	2008-2012	36	7	2438	2304	148	30	7.1	1.5
	Total	85	42	8177	8682				
35-41	1993-1997	16	12	6914	7609	23	16	1.6	1.1
	1998-2002	20	14	4241	4620	47	30	3.2	2.1
	2003-2007	47	13	3542	2864	133	45	8.9	3.1
	2008-2012	42	20	3247	2026	129	99	8.7	6.7

	Total	125	59	17944	17119	
--	--------------	------------	-----------	--------------	--------------	--

Table 4

Incidence and conditional probability of ART treatments in cancer survivors and siblings according to age and time period of drug purchase

Figure 1. Female cancer survivors and their female siblings. Criteria for inclusion and number of women and person years included in the final analysis. CPR, Central population register; MBR, Medical Birth Register; RPM, Reimbursement Register for Prescribed Medicines
*between 1987-2013

Figure 2. Incidence rates for ovulation induction and assisted reproductive technology (ART) in cancer survivors and siblings according to age at drug purchase in different time periods

THE DIFFERENCE OF BREAKTHROUGH MOMENTS

WITH AN INTEGRATED SOLUTION FOR
GROUNDBREAKING SINGLE-CELL RESEARCH

BD Accuri™ C6 Plus Personal Flow Cytometer

BD FACSCelesta™ Cell Analyzer

BD LSRFortessa™ X-20 Cell Analyzer

BD FACSMelody™ Cell Sorter

FlowJo™ Software

One of the largest portfolios of reagents

Discover more >